TORONTO and HOUSTON, May 16,
2019 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or "the Company") (TSX: MDNA, OTCQB:
MDNAF), a clinical stage immuno-oncology company, today announced
that Dr. Dina Randazzo of
Duke University, will present updates
related to the recently completed Phase 2b clinical trial of MDNA55 for the
treatment of recurrent glioblastoma at the 2019 Annual Meeting
of the American Society of Clinical Oncology (ASCO) to be held from
May 31 to June 4, 2019 in
Chicago, Illinois.
The details of the poster presentation are as follows:
Title: MDNA55: A Locally Administered IL4 Guided
Toxin as a Targeted Treatment for Recurrent Glioblastoma
Session Title: Central Nervous System Tumors
Presenter: Dr. Dina
Randazzo, DO, MS; Assistant Professor of Neurosurgery,
Duke University Medical Center
Poster #: 228 Abstract: #2039
Date/Time: Sunday, June 2, 2019 from 8:00am to 11:00am
Location: Hall A, McCormick Place Convention Center,
2301 S King Dr, Chicago, IL
60616
In addition, Medicenna will have two abstracts published in the
Conference Proceedings reporting (1) the use of multi-parametric
MRI techniques to monitor tumor response in rGBM patients treated
with MDNA55 in the recently completed Phase 2b clinical trial, and (2) preclinical data on
its immuno-oncology pipeline candidate MDNA109.
Title: Multi-parametric MRI as supplement to mRANO
criteria for response assessment to MDNA55 in Adults with Recurrent
or Progressive Glioblastoma.
First Author: Diana Roettger,
PhD
Abstract: #e13559
Title: MDNA109: An Interleukin-2 Superkine
Exhibiting Improved CD8 T-cell Activating Properties in the Tumor
Microenvironment.
First Author: Moutih Rafei, PhD
Abstract: #e14220
Abstracts of the company's presentations are available
at: abstracts.asco.org
About Medicenna
Medicenna is a clinical stage immunotherapy company developing
novel highly selective versions of IL-2, IL-4 and IL-13 Superkines
and first in class Empowered Cytokines™ (ECs). Our mission is to
become the leader in the development and commercialization of ECs
and Superkines for the treatment of a broad range of cancers and
immune-mediated diseases. MDNA55 is Medicenna's lead EC that has
completed enrolling in a multi-centre Phase 2b clinical
trial for the treatment of recurrent glioblastoma, funded in part
by the Cancer Prevention and Research Institute of Texas (CPRIT). MDNA55 has secured Orphan Drug
Status from the United States Food and Drug Administration (FDA)
and the European Medicines Agency as well as Fast Track Designation
from the FDA for the treatment of rGBM. For more information,
please visit www.medicenna.com.
View original
content:http://www.prnewswire.com/news-releases/medicenna-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-asco-annual-meeting-300851280.html
SOURCE Medicenna Therapeutics Corp.